

Claims

1. An anti-CD38 antibody or antibody fragment for use in the treatment of an immune complex-mediated disease in a subject.
2. Use of an anti-CD38 antibody or antibody fragment in the treatment of an immune complex-mediated disease.
3. An anti-CD38 antibody or antibody fragment for use according to claim 1, wherein the immune complex - mediated disease is a kidney disease.
4. An anti-CD38 antibody or antibody fragment for use according to claim 3, wherein the immune complex - mediated disease is selected from IgA nephropathy, lupus nephritis, Henoch-Schönlein purpura nephritis, post-streptococcal glomerulonephritis or drug-induced immune complex - mediated diffuse proliferative glomerulonephritis.
5. An anti-CD38 antibody or antibody fragment for use according to claim 4, wherein the IgA nephropathy is a galactose-deficient IgA1 antibody (Gd-IgA1) and anti-galactose-deficient IgA1 antibody (anti-GD-IgA1) positive IgA nephropathy.
6. An anti-CD38 antibody or antibody fragment for use according to any of the preceding claims, wherein the antibody comprises a HCDR1 region of amino acid sequence SEQ ID NO.: 1, a HCDR2 region of amino acid sequence SEQ ID NO.: 2, a HCDR3 region of amino acid sequence SEQ ID NO.: 3, and a LCDR1 region of amino acid sequence SEQ ID NO.: 4, a LCDR2 region of amino acid sequence SEQ ID NO.: 5 and a LCDR3 region of amino acid sequence SEQ ID NO.: 6.
7. An anti-CD38 antibody or antibody fragment for use according to claim 6, wherein anti-CD38 said antibody or antibody fragment comprises a variable heavy chain (VH) region of SEQ ID NO.: 7 and a variable light chain (VL) region of SEQ ID NO.: 8.

8. An anti-CD38 antibody or antibody fragment for use according to any of the preceding claims, wherein said antibody or antibody fragment specific for CD38 is an IgG1.
9. An anti-CD38 antibody or antibody fragment for use according to any of the preceding claims, wherein said antibody or antibody fragment specific for CD38 is a human antibody.
10. An anti-CD38 antibody or antibody fragment for use according to any of the preceding claims, wherein the antibody depletes plasma cells by antibody-dependent cell-mediated cytotoxicity (ADCC) and/or antibody-dependent cell-mediated phagocytosis (ADCP).
11. An anti-CD38 antibody or antibody fragment for use according to any of the preceding claims, wherein administration of said anti-CD38 antibody or antibody fragment leads to a reduction of immune complexes.
12. An anti-CD38 antibody or antibody fragment for use according to any one of claims 5 to 11, wherein the immune complex comprises Gd-IgA1 and anti-GD-IgA1 antibodies.
13. An -CD38 antibody or antibody fragment for use according to claim 11 or 12, wherein the immune complex is deposited in the glomeruli of the kidney.
14. The anti-CD38 antibody or antibody fragment for use according to any of the preceding claims, wherein the antibody or antibody fragment will be dosed depending on subject body weight.
15. The anti-CD38 antibody or antibody fragment for use according to claim 14, wherein the antibody or antibody fragment will be dosed in at least 2 doses, at least 5 doses, or at least 9 doses according to Table 6.
16. The anti-CD38 antibody or antibody fragment for use according to any of the preceding claims, wherein the subject to be treated is characterized by proteinuria at screening of ≥ 1.0 g/day.